Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition

An interview with: Anisha B Patel MD, Associate Professor of Dermatology, Division of Internal Medicine, MD Anderson Cancer Center, Houston TX CHICAGO, USA—Acneiform rash toxicities caused by anti- epidermal growth factor receptor (EGFR) therapies were markedly reduced among patients with colorectal cancer in a double-blind placebo-controlled, randomized phase two clinical trial that assessed the efficacy of a topical BRAF inhibitor gel designed to treat these skin lesions without affecting cancer treatment. The results were presented at the 2025 Annual Meeting of the American Association for Cancer Research (AACR). First author of the study, Anisha Patel MD, Associate Professor of Dermatology at the MD Anderson Cancer Center in Houston Texas, gave Audio Journal of Oncology  correspondent Peter Goodwin more details about the findings AACR Abstract Title: “A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies”

There are no comments yet.

Please log in to write the first comment.